Enveric Biosciences Q2 net loss widens

Overview

• US biotechnology firm's Q2 net loss widened yr/yr

• Company advanced IND-enabling studies for EB-003 and reported new preclinical data

• Company expanded IP portfolio and raised $6.5 mln through offerings and warrant exercises

Outlook

• Company aims to complete IND-enabling activities and submit IND for EB-003 in H2 2026

• Enveric expects to initiate first-in-human Phase 1 trial for EB-003 after IND submission

• Company sees recent FDA guidance and industry investment as supportive of its neuroplastogen strategy

Result Drivers

• R&D PROGRESS - Co advanced IND-enabling studies and reported additional preclinical data for EB-003, per CEO Joseph Tucker

• IP PORTFOLIO EXPANSION - Co secured new US patent for EVM301 Series and received Notice of Allowance for EVM401 Series

• FUNDRAISING - Co raised $5.0 mln through private placement and $1.5 mln from warrant exercises in Q2

Company press release: ID:nBw1x3xRda

Key Details

Reuters Recommended Reads

• Aug 13 - Ensysce Biosciences Q2 net loss widens on higher R&D costs

• Aug 12 - Definium says LSD-based pill reduces anxiety in late-stage study

• Aug 14 - Acurx Pharmaceuticals Q2 loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)